Casale Thomas B
Center for Allergy, Asthma and Immunology, Creighton University, Omaha, NE 68131, USA.
Postgrad Med. 2003 Feb;113(2 Suppl):15-20. doi: 10.3810/pgm.02.2003.suppl25.133.
The clinical significance of small airway pathology makes these passages an important therapeutic target in asthma. Conventional chlorofluorocarbon-based formulations of inhaled corticosteroids for asthmatic inflammation produce aerosols with a relatively large particle size, and as such, offer poor access to the small airways. New corticosteroid formulations use hydrofluoroalkane propellants with a smaller average particle size, allowing better access to the distal lung. By extending the delivery of this medication to the peripheral lung and by increasing the efficiency of lung targeting, these new corticosteroid formulations provide more effective treatment at reduced drug doses.
小气道病理的临床意义使这些气道成为哮喘治疗的重要靶点。传统的基于氯氟烃的吸入性皮质类固醇制剂用于哮喘炎症，会产生粒径相对较大的气雾剂，因此难以进入小气道。新型皮质类固醇制剂使用平均粒径较小的氢氟烷烃推进剂，能更好地进入远端肺部。通过将这种药物输送扩展到外周肺并提高肺部靶向效率，这些新型皮质类固醇制剂能以更低的药物剂量提供更有效的治疗。
